Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr McCarthy on Neutrophil-Mediated Immunosuppression in Multiple Myeloma

June 24th 2024

Philip McCarthy, MD, discusses findings from an investigation, assessing the impact of neutrophils within the tumor microenvironment of multiple myeloma.

Dr Rifkin on the Evaluation of Prophylactic Tocilizumab Prior to Teclistamab in R/R Myeloma

June 24th 2024

Robert M. Rifkin, MD, FACP, discusses the use of prophylactic tocilizumab to reduce teclistamab-related CRS in relapsed/refractory myeloma.

Dr Biran on Current Unmet Needs in Relapsed/Refractory Multiple Myeloma

June 18th 2024

Noa Biran, MD, discusses the investigation of belantamab mafodotin plus bortezomib and dexamethasone in multiple myeloma.

Dr Mateos on Belantamab Mafodotin Plus Bortezomib/Dexamethasone in R/R Myeloma

June 18th 2024

María-Victoria Mateos, MD, PhD, discusses findings for belantamab mafodotin plus bortezomib and dexamethasone.

Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma

June 18th 2024

Ide-cel induced durable responses and had a favorable risk-benefit profile in patients with functionally high-risk multiple myeloma.

Dr Raje on the DREAMM-7 and DREAMM-8 Trials in Multiple Myeloma

June 17th 2024

Noopur S. Raje, MD, and Yan Leyfman, MD, discuss the phase 3 DREAMM-7 and DREAMM-8 trials on OncLive News Network: On Location.

Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma

June 17th 2024

Linvoseltamab induced durable responses in patients with relapsed or refractory multiple myeloma, including those with high-risk features.

Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma

June 16th 2024

Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.

Dr Jagannath on Linvoseltamab vs Teclistamab in Triple-Class–Exposed R/R Myeloma

June 14th 2024

Sundar Jagannath, MBBS, discusses outcomes with linvoseltamab vs teclistamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Ide-Cel Generates Favorable PFS Outcomes in R/R Multiple Myeloma With Lower Tumor Burden

June 14th 2024

Ide-cel induced improved PFS outcomes in patients with relapsed/refractory multiple myeloma with characteristics including lower tumor burden.

Dr Neparidze on Belantamab Mafodotin Plus Elotuzumab in R/R Myeloma

June 14th 2024

Natalia Neparidze, MD, discusses combining belantamab mafodotin with elotuzumab in patients with RRMM.

Quadruplet Therapy and Early-Line CAR T-Cell Therapy Approvals Mark Shifting Standards in Multiple Myeloma

June 13th 2024

Minoo Battiwalla, MD, MS, discusses the impact of earlier-line FDA approvals for CAR T-cell therapies on treatment outcomes in multiple myeloma.

Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies

June 12th 2024

Talquetamab proved safe and effective for relapsed/refractory myeloma, even in patients with comorbidities.

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

June 7th 2024

Linvoseltamab elicited outcomes equivalent to those seen with teclistamab in patients with triple-class exposed relapsed/refractory multiple myeloma.

Teclistamab Triplet Shows Manageable Safety, Early Efficacy in Transplant-Ineligible Myeloma

June 6th 2024

Teclistamab plus daratumumab and lenalidomide had a manageable safety profile in patients with transplant-ineligible, newly diagnosed multiple myeloma.

Daratumumab Retreatment Leads to Responses in Relapsed/Refractory Myeloma

June 5th 2024

Retreatment with daratumumab-based regimens led to a similar ORR vs initial daratumumab treatment in relapsed/refractory myeloma.

Updated Analysis From MajesTEC-1 Confirms CRS Reduction With Prophylactic Tocilizumab in Relapsed/Refractory Myeloma

June 5th 2024

Updated Analysis from Phase 1/2 MajesTEC-1 trial support the use of prophylactic tocilizumab to reduce the risk of cytokine release syndrome associated with outpatient administration of teclistamab.

Dr Landgren on the Rationale for Utilizing MRD as a Clinical Trial End Point in Myeloma

June 4th 2024

Ola Landgren, MD, PhD, discusses the background for utilizing MRD as a clinical trial end point when evaluating multiple myeloma treatment.

D-VRd Boosts MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

June 4th 2024

Daratumumab plus VRd increased rates of MRD negativity in newly diagnosed, transplant-eligible multiple myeloma.

Isa-VRd Prolongs PFS in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

June 4th 2024

Isatuximab plus VRd produced a statistically significant improvement in PFS vs VRd in newly diagnosed, transplant-ineligible multiple myeloma.